Valuation: Day One Biopharmaceuticals, Inc.

Market Cap 2.22B 1.99B 1.82B 1.66B 3.11B 211B 3.17B 21.77B 8.77B 111B 8.35B 8.17B 351B P/E 2024
-12.4x
P/E 2025 -8.96x
Enterprise Value 1.79B 1.59B 1.46B 1.33B 2.5B 169B 2.55B 17.48B 7.05B 89.25B 6.7B 6.56B 282B EV / Sales 2024
5,707,524x
EV / Sales 2025 3,278,601x
Free-Float
94.59%
Yield 2024 *
-
Yield 2025 -
1 day+0.19%
Current year+131.01%
Current year 8.35
Extreme 8.35
21.53
1 year 7.1
Extreme 7.105
21.53
3 years 5.64
Extreme 5.635
21.53
5 years 5.44
Extreme 5.44
28.35
10 years 5.44
Extreme 5.44
28.7
Manager TitleAgeSince
Director of Finance/CFO 49 01/02/2021
President - 23/04/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 23/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
23/04/26 Issuer sale

Director

272,508 0.2638%
23/04/26
Access Industries, Inc. (New York)
TenderCompany 13,756,908 13.3177%
23/04/26 Issuer sale

Chief Technology Officer

854,272 0.8270%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%+189.38%+81.84% 2.22B
-0.87%+9.76%+56.60%+141.94% 1,263B
-1.47%+1.04%+44.46%+79.09% 658B
-2.16%+0.61%+36.11%+101.38% 521B
-1.54%+0.18%+53.06%+66.79% 391B
-0.55%+5.82%+80.39%+44.68% 369B
-1.69%+3.17%+32.18%+55.35% 307B
-0.72%+7.83%+12.10%+33.76% 290B
+0.24%+4.86%+57.35%+74.89% 252B
-0.19%+6.93%+39.03%+108.90% 212B
Average -0.90%+5.34%+60.07%+78.86% 426.42B
Weighted average by Cap. -1.13%+6.59%+48.41%+92.76%

Financials

2024 2025
Net sales 131.16 117.1 107.46 97.75 183.27 12.42K 186.92 1.28K 517.36 6.55K 492.26 481.77 20.7K 158.18 141.22 129.59 117.89 221.02 14.98K 225.43 1.55K 623.95 7.9K 593.67 581.02 24.97K
Net income -95.5M -85.26M -78.24M -71.17M -133M -9.04B -136M -934M -377M -4.77B -358M -351M -15.07B -107M -95.82M -87.93M -79.98M -150M -10.16B -153M -1.05B -423M -5.36B -403M -394M -16.94B
Net Debt -529M -472M -433M -394M -739M -50.09B -754M -5.18B -2.09B -26.44B -1.99B -1.94B -83.51B -438M -391M -359M -327M -612M -41.5B -625M -4.29B -1.73B -21.9B -1.65B -1.61B -69.18B
Projected Income Statement - Annual - Day One Biopharmaceuticals, Inc.
Logo Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company's commercial product OJEMDA (tovorafenib), is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor that inhibits both monomeric and dimeric RAF kinase. OJEMDA is the only systemic therapy for pLGG that offers once-weekly dosing, with or without food, as a tablet or oral suspension. Its BRAF products, such as vemurafenib and encorafenib, are referred to as type I RAF inhibitors, which only inhibit RAF monomers and are therefore limited to use in BRAF V600-altered tumors. The DAY301 candidate, is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody, or mAb, conjugated with a topoisomerase I inhibitor (exatecan mesylate) via stable and hydrophilic modified valine-alanine (VA) cleavable linker.
Employees
178
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Day One Biopharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. DAWN Stock